Source: European Medicines Agency (EU) Revision Year: 2024 Publisher: Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland
Xolair 150 mg solution for injection in pre-filled syringe.
Xolair 300 mg solution for injection in pre-filled syringe.
Xolair 150 mg solution for injection in pre-filled pen.
Xolair 300 mg solution for injection in pre-filled pen.
| Pharmaceutical Form |
|---|
|
Solution for injection (injection). Clear to slightly opalescent, colourless to pale brownish-yellow solution. |
Xolair 150 mg solution for injection in pre-filled syringe: Each pre-filled syringe contains 150 mg of omalizumab* in 1 ml solution.
Xolair 300 mg solution for injection in pre-filled syringe: Each pre-filled syringe contains 300 mg of omalizumab* in 2 ml solution.
Xolair 150 mg solution for injection in pre-filled pen: Each pre-filled pen contains 150 mg of omalizumab* in 1 ml solution.
Xolair 300 mg solution for injection in pre-filled pen: Each pre-filled pen contains 300 mg of omalizumab* in 2 ml solution.
* Omalizumab is a humanised monoclonal antibody produced in a Chinese hamster ovary (CHO) mammalian cell line by recombinant DNA technology.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Omalizumab |
Omalizumab is a recombinant DNA-derived humanised monoclonal antibody that selectively binds to human immunoglobulin E (IgE) and lowers free IgE levels. The antibody is an IgG1 kappa that contains human framework regions with the complementary-determining regions of a murine parent antibody that binds to IgE. |
| List of Excipients |
|---|
|
Arginine hydrochloride |
Xolair 150 mg solution for injection in pre-filled syringe is supplied as 1 ml solution in a pre-filled syringe barrel (type I glass) with 26-gauge staked needle (stainless steel), (type I) plunger stopper and needle cap.
Pack sizes: packs containing 1 pre-filled syringe, and multipacks containing 4 (4 × 1); 6 (6 × 1) or 10 (10 × 1) pre-filled syringes.
Xolair 150 mg solution for injection in pre-filled syringe is supplied as 1 ml solution in a pre-filled syringe barrel (type I glass) with 27-gauge staked needle (stainless steel), (type I) plunger stopper and needle cap.
Pack sizes: packs containing 1 pre-filled syringe, and multipacks containing 3 (3 × 1) or 6 (6 × 1) pre-filled syringes.
Xolair 300 mg solution for injection in pre-filled syringe is supplied as 2 ml solution in a pre-filled syringe barrel (type I glass) with 27-gauge staked needle (stainless steel), (type I) plunger stopper and needle cap.
Pack sizes: packs containing 1 pre-filled syringe, and multipacks containing 3 (3 × 1) or 6 (6 × 1) pre-filled syringes.
Xolair 150 mg solution for injection in pre-filled pen is supplied as 1 ml solution in a pre-filled pen barrel (type I glass) with 27-gauge staked needle (stainless steel), (type I) plunger stopper and needle cap.
Pack sizes: packs containing 1 pre-filled pen, and multipacks containing 3 (3 × 1) or 6 (6 × 1) pre-filled pens.
Xolair 300 mg solution for injection in pre-filled pen is supplied as 2 ml solution in a pre-filled pen barrel (type I glass) with 27-gauge staked needle (stainless steel), (type I) plunger stopper and needle cap.
Pack sizes: packs containing 1 pre-filled pen, and multipacks containing 3 (3 × 1) or 6 (6 × 1) pre-filled pens.
Not all pack sizes may be marketed.
Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland
Xolair 150 mg solution for injection in pre-filled syringe:
EU/1/05/319/008
EU/1/05/319/009
EU/1/05/319/010
EU/1/05/319/011
EU/1/05/319/024
EU/1/05/319/025
EU/1/05/319/026
Xolair 300 mg solution for injection in pre-filled syringe:
EU/1/05/319/012
EU/1/05/319/013
EU/1/05/319/014
Xolair 150 mg solution for injection in pre-filled pen:
EU/1/05/319/027
EU/1/05/319/028
EU/1/05/319/029
Xolair 300 mg solution for injection in pre-filled pen:
EU/1/05/319/015
EU/1/05/319/016
EU/1/05/319/017
Date of first authorisation: 25 October 2005
Date of latest renewal: 22 June 2015
| Drug | Countries | |
|---|---|---|
| XOLAIR | Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.